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Abstract: The crucial event in the development of transmissible spongiform encephalopathies (TSEs) is the 
conformational change of a host-encoded membrane protein - the cellular PrP
C - into a disease associated, 
fibril-forming isoform PrP
Sc. This conformational transition from the -helix-rich cellular form into the mainly -
sheet containing counterpart initiates an ‘autocatalytic’ reaction which leads to the accumulation of amyloid 
fibrils in the central nervous system (CNS) and to neurodegeneration, a hallmark of TSEs. 
The exact molecular mechanisms which lead to the conformational change are still unknown. It also remains to 
be brought to light how a polypeptide chain can adopt at least two stable conformations. This review focuses 
on structural aspects of the prion protein with regard to protein-protein interactions and the initiation of prion 
protein misfolding. It therefore highlights parts of the protein which might play a notable role in the 
conformational transition from PrP
C to PrP
Sc and consequently in inducing a fatal chain reaction of protein 
misfolding. Furthermore, features of different proteins, which are able to adopt insoluble fibrillar states under 
certain circumstances, are compared to PrP in an attempt to understand the unique characteristics of prion 
diseases. 
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INTRODUCTION 
The Prion Protein (PrP) belongs to the class of 
amyloid-forming proteins which are, in some cases, 
associated with certain diseases. The cellular prion 
protein (PrP
C) is a membrane associated protein 
occurring in a wide range of eukaryotic cells. The wide 
distribution among mammalian species and the high 
conservation of PrP
C indicates a role of general 
importance. However, the physiological function of 
PrP
C is still unknown.  
According to the ‘protein-only’ hypothesis [1], PrP
C
is able to undergo a conformational transition into an 
insoluble isoform known as PrP
Sc (‘Sc’ for ‘scrapie’) 
and which is thought to be the agent that causes 
transmissible spongiform encephalopathies (TSEs). 
TSEs are fatal neurodegenerative diseases, including 
among others Creutzfeldt-Jakob-Disease (CJD) in 
humans, scrapie in sheep and goats, as well as bovine 
spongiform encephalopathy (BSE) in cattle [2, 3]. It is 
the transmissibility of prion disorders which distin-
guishes TSEs of other protein misfolding diseases. 
There is evidence that the decisive process i.e., the 
irreversible conversion of the physiological membrane 
associated cellular prion protein (PrP
C) into its disease-
related proteinase K (PK) resistant counterpart PrP
Sc,
initiates an ‘autocatalytic’ reaction which leads to the 
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accumulation of amyloid in the central nervous system 
(CNS) and, through still unknown mechanisms, to 
neurodegeneration [4, 5]. 
A noteworthy, and heretofore unexplained, 
characteristic of TSEs is the existence of different 
strains, which can be distinguished due to specific 
incubation times and clinical signs in vivo [6] as well as 
by distinct biochemical or immunohistological charac-
teristics  in vitro [7-9]. It is still unknown how strain-
specific characteristics are supposed to be transmitted 
by a protein itself. Structural determinants such as 
glycosylation are thought to be involved in strain-
dependent specification of PrP
Sc structures and are a 
characteristic distribution in affected brains [10, 11]. 
However, the occurrence of prion strains and the 
protein-only hypothesis have not yet been reconciled. 
Despite proceeding findings in prion research, the 
exact mechanisms that underlie the conformational 
change or conversion of PrP
C, as well as those that 
cause the typical pathological pattern of TSEs, remain 
an enigma [2, 12]: hence, the development of rational 
approaches to diagnosis and therapy are restricted [13-
15].  
The feature to undergo induced or spontaneous 
misfolding was shown to depend on structural aspects 
of PrP
C, such as the amino acid sequence [16-19], the 
highly flexible amino terminal region of the protein [20] 
as well as secondary structure elements [21, 22] and 
posttranslational modification elements [11, 23]. The 
remarkable peculiarity of PrP to adopt several struc-
turally favourable states requires a detailed contemp-
lation of distinct structural parts of PrP
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possible role in PrP
C-PrP
Sc interaction, misfolding and 
disease transmission. Cofactors, like metal ions [24, 
25] or proteins [26, 27], are also thought to be involved 
in the structural determination of PrP, but the manner in 
which they influence structure and interaction with 
other molecules is yet to be determined. Furthermore, 
whether they have an effect in preventing prion protein 
misfolding is also in question.  
The purpose of this review is to highlight different 
sections of PrP
C and their possible role in PrP
C-PrP
Sc
interaction and prion protein misfolding. Additionally, 
features of other proteins that are able to adopt 
insoluble fibrillar states under certain circumstances, 
are compared to PrP with regard to our understanding 
of the unique characteristics of prion diseases. 
STRUCTURE DETERMINATION FOR PrP
C
The molecular structure of PrP
C at atomic resolution 
has been determined by nuclear magnetic resonance 
(NMR) spectroscopy and X-ray crystallography. PrP
C
consists of a long and flexible amino terminal region 
spanning up to amino acid (aa) residue 121 and a 
structured carboxy terminal domain. This globular 
domain harbours two short sheet-forming anti-parallel 
-strands (aa 128 to 130 and aa 160 to 162 in murine 
PrP
C) and three -helices (helix I: aa 143 to 153; helix 
II: aa 171 to 192; helix III: aa 199 to 226 in murine 
PrP
C) [28]. The length of the unprocessed translation 
product is 256 amino acids. In the course of its transit 
through the ER and Golgi apparatus, post-translational 
modifications occur, such as the removal of a N-
terminal signal sequence (1-22); the formation of an 
internal helix II and III stabilizing disulfide bond 
(between aa 179 and aa 214); the attachment of N-
linked oligosaccharide chains (at aa 180 and aa 196); 
and the replacement of the carboxy terminus (at aa 
231) by a glycosylphosphatidylinositol (GPI) anchor 
[29]. Fully processed (murine) PrP
C therefore contains 
only 209 amino acids, representing codons 23-231 of 
the prion ORF. The glycosylation can be missing or 
occur at either one or both sites so that cells harbour 
non-, mono-, as well as diglycosylated isoforms of PrP
C
(Fig. (1)). 
MODEL STRUCTURES OF PrP
Sc 
In contrast to PrP
C, the three-dimensional structure 
of PrP
Sc has not yet been fully established, since this 
protein could not be purified in sufficient quantity and 
quality in a soluble, non-aggregated form. 
Amyloidal fibrillar structures are characterized by 
tinctorial assays using Congo Red and Thioflavin T, far 
ultraviolet CD-spectra which identify -structures and 
typical anisotropic 'cross-' X-ray diffraction pattern. X-
ray diffraction studies of amyloid fibres have shown that 
their protofilament cores all contained a 'cross-'
scaffold in which -strands are arranged 
perpendicularly and -sheets are parallel to the axis of 
the fibre. The stabilization of the core structure is 
basically provided by hydrogen bonds and other 
interactions, including the polypeptide main chain. 
Some amino acids at certain residues may support the 
process of arranging fibrillar structures. An alternation 
of polar and hydrophobic residues can result in a 
formation of the same kind of -sheet structures that 
are found in amyloid fibrils [30]. Crystal structure 
analysis of short oligopeptides, which are parts of 
amyloid-forming proteins, revealed that segments of 
four to seven amino acid residues are sufficient to form 
fibrils. The assumption is that amyloid-like fibrils are 
formed by two tightly interdigitating -sheets in a 
zipper-like manner, allowing nucleation to fibril forming 
aggregates. Alternately, this process can also start by 
the unmasking of short zipper-forming segments, which 
then stack into -sheets. 
Fig. (1). Schema of the cellular mouse prion protein (left): the N-terminal signal sequence (aa 1-22) is removed during 
posttranslational processing. The unstructured region (aa 23-121) harbors five octarepeats, which function as binding site for 
bivalent ions, such as Cu
2+. The neurotoxic peptide (aa 106-126) is show in yellow. The globular domain consists of two very 
short -strands (aa 128 to 130 and aa 160 to 162; light green) and three -helices (aa 143 to 153, aa 171 to 192, aa 199 to 226; 
red). The disulfide bond between aa 179 and aa 214 stabilizes the three dimensional structure of the protein. Two glycosylation
sites are located at aa 180 and 196, where oligosaccharide chains are linked to the polypeptide chain. A GPI anchor (aa 231) 
attaches the protein to the cell membrane, as shown in the right Picture. 
DeMarco, M.L., and Daggett, V. (2005). Comptes Rendus Biol., 328, 847-862. 
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However, on the basis of cryoelectron microscopy 
and by the means of structural modeling based on 
similar common protein structures, it has been 
discovered that PrP
Sc contains ß-sheets in the region of 
aa 81-95 to aa 171, while the carboxy terminal 
structure is supposedly preserved. These ß-sheets 
form a left-handed beta-helix. Three PrP
Sc  molecules 
are believed to form a primary unit and therefore build 
the basis for the so-called scrapie-associated fibrils [31] 
(Fig. (2)). 
The increase in the content of -sheet structures 
results in insolubility in mild detergent fluids and causes 
partial resistance to enzymatic degradation of the 
pathogenic isoform PrP
Sc. If PrP
Sc is treated with 
proteolytic enzymes, only the N-terminal amino acids 
(aa) up to residues 81-95 (depending on the TSE agent 
and the proteolytic conditions) are digested [32, 33], 
leaving the remaining PrP
Sc reaching from aa 81-95 to 
aa 231. The increased resistance to proteolysis leads 
to an accumulation of PrP
Sc, which can be made visible 
by special amyloid or immunohistochemical staining. 
PrP
Sc is also deposited outside the cell as well as in the 
lysosomal-endosomal compartments within the cell 
[34]. The disease-causing agents are PrP
Sc aggregates 
that act as templates for the conversion; its catalytic 
activity depends on the size of the particle. PrP
Sc
particles which consist of only 14-28 PrP molecules 
exhibit the highest rate of infectivity and conversion 
[35]. 
PRION PROTEIN MISFOLDING DISEASES – A 
COMMON PATHOLOGICAL PHENOMENON  
Apart from prion diseases, there are a number of 
other protein misfolding diseases: Alzheimer’s disease, 
Parkinson’s disease, Huntington’s disease, 
spinocerebellar ataxias, type II diabetes, amyotrophic 
lateral sclerosis, as well as diffuse Lewy body dementia 
and the fronto-temporal dementias. Studying the key 
molecular mechanisms involved in prion diseases may 
also help to understand these other amyloidoses. 
Inducible proteinopathies, such as amyloid A 
amyloidosis or apolipoprotein A II amyloidosis, show 
remarkable similarities to prion diseases [36]. Most 
recently Meyer-Luehmann [37] reported that in 
Alzheimer's disease the exogenous induction of 
cerebral ß-amyloidogenesis is governed by agent and 
host factors. The striking parallels of infectious prion 
disorders to the above-mentioned putatively non-
infectious protein misfolding and assembly diseases 
make it more and more difficult to delimitate their 
pathological mechanisms from each other.  
Of all the proteins known to undergo misfolding, the 
prion protein has been, and will likely continue to be, 
one of the most thoroughly researched. These 
investigations targeted the structural stability of PrP
Sc
and PrP
C, or they examined the propensity of PrP
C to 
be folded into PrP
Sc, using cell-free systems, infected 
cell lines or transgenic mice. Structural stability studies 
on PrP
Sc include partial or consecutive protein 
Fig. (2). Model of a three dimensional structure for PrP
Sc: the -sheets fold into -helices. Three of these -helix molecules form 
the basic unit for a PrP
Sc-fibril (right). 
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denaturation steps by urea or guanidinium; subsequent 
measurements include using a conformation 
dependent immunoassay (to determine the epitope 
accessibility to antibodies) or circular dichroism 
spectra. Similar experiments have also been carried 
out to determine the unfolding characteristics and 
structural stability of PrP
C. However, PrP
C conversion 
assays are the most frequently used approaches and 
include a large variety of different experimental setups.  
Protein folding and hence misfolding is determined 
by the primary structure of a polypeptide chain, but the 
complex process of protein folding kinetics has been a 
major topic for decades and is still not completely 
understood. Despite numerous models for protein 
folding, there also exist various theories as to how 
misfolding could be explained.  
It is likely that PrP
C undergoes some intermediate 
states of structural organisation before finally ending up 
as part of an amyloid fibril. Misfolding can only take 
place when the native structure of a globular protein is 
at least partially unfolded or degraded. Beside the prion 
protein, there are numerous other soluble proteins 
which can self-assemble to an amyloidogenic state 
and, as far as is known, display similar features 
concerning their structure [38].  
A certain tertiary structure of a protein represents 
the equilibrium of the polypeptide molecule with the 
chemical environment, defined by the surrounding 
solvent, salt concentrations and pH. The overall folding 
stability, i.e. the free energy term of globular proteins is 
in the range of one or two hydrogen bonds which allow 
the transition to alternative conformations in the energy 
landscape without the threshold of high transition 
energies. As a result, for several proteins, alternative 
conformers are now known [39, 40]: rapid refolding 
under physiological conditions has been shown for 
spider-silk proteins that form -sheet rich fibres 
contingent upon the rapid decrease of sodium, 
increase of potassium concentration and a drop in the 
pH (8 – 6) [41, 42]. If buffer conditions are changed for 
the all helical apo-myoglobin, then -strand containing, 
fibre-forming aggregates occur [43, 44]. The authors 
suggest that cross--conformation is dominated by 
protein main chain interactions common to different 
polypeptides, whereas specific side chain interactions 
will define the characteristic main chain fold of globular 
proteins. Furthermore, they conclude that evolutionary 
adaptation, including mutational sequence variation 
and molecular chaperones, suppresses amyloid 
formation of globular proteins in vivo. Fibril formation of 
PrP can also be initiated by certain buffer conditions 
without the requirement of an infectious PrP
Sc seed 
[45]. Spontaneous protein misfolding may occur more 
frequently under physiological conditions than is 
generally assumed. Cellular factors and pathways 
could be of major relevance in regards to disease 
prevention or initiation. 
Chaperones may have a key role in preventing 
pathogenic effects of misfolding and aggregation. An 
interesting example is the extracellular chaperone 
clusterin, which inhibits amyloid formation of human 
lysozyme [46]. Clusterin interacts with oligomeric 
prefibrillar species, which are present in the nucleation 
phase prior to aggregation. Apparently, these 
interactions support the dissociation of the prefibrillar 
intermediates into native monomers. As for PrP, 
chaperones have been shown to play an 
interchangeable role: certain heat shock proteins are 
able to promote conversion, whereas others inhibit 
misfolding [47]. The chaperon BiP, which is present in 
the endoplasmatic reticulum (ER), has been shown to 
bind to certain forms of PrP that were retained in the 
ER due to incomplete processing [27]. Within the ER, 
BiP is believed to maintain proper folding of PrP by 
binding to defective forms for an extended period of 
time. In this way, the defective forms can finally be 
degraded by the proteasomal pathway.  
Due to their occurrence in amyloids, there is 
evidence for the assumption that nucleic acids, lipids 
and glycosaminoglycans (GAGs) might play a role as 
cofactors in amyloidogenesis. For this reason they 
could be a useful therapeutic target not only for prion 
disorders but also for other protein misfolding diseases. 
The significant effects of possible cofactors have 
been demonstrated in numerous experiments. In an 
interesting study by Yin and colleagues [48], it was 
shown that recombinant PrP harbouring different 
pathogenic mutations had a more exposed amino 
terminus and bound more strongly to glycosa-
minoglycans. As common components of amyloid [49] 
GAGs are found in PrP
Sc in vivo [50], it has been 
shown that they facilitate the conversion of PrP
C into 
PrP
Sc in vitro [51], as well as PrP-aggregation [48]. 
Lipids and nucleic acids also bind to PrP
C and are 
detectable in PrP
Sc-aggregates [52-54]; additionally, 
they may facilitate PrP-conversion by functioning as a 
scaffold that binds and concentrates PrP
C in order to 
provide high amounts of substrate for a conversion into 
PrP
Sc.
EFFECTS OF THE PRIMARY STRUCTURE OF 
PRION PROTEIN ON ITS MISFOLDING PRO-
PENSITY  
In light of recent studies, significant differences 
among different species concerning the tertiary 
structure of PrP
C are unlikely due to a high degree of 
structural and organizational homology between mam-
malian PrP sequences and structures [55]. However, 
there are indeed major associations between the 
convertibility of the various PrP
Cs and the variability of 
single amino acids at certain positions within PrP
C.
Single amino acids at certain positions of PrP
C can 
have striking effects in relation to either the 
susceptibility to TSEs or the chance to develop 
inherited forms of human prion diseases. There are 
more than twenty mutations of the prion protein gene 
(prnp) that are known to be associated with or that are 
directly linked to human TSEs [56]. A well known 
polymorphism in the human PrP gene is located at 
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valine: it influences the susceptibility to sporadic [57] or 
acquired TSEs [58], as well as the age of onset of the 
disease [59]. It was demonstrated that this 
polymorphism even has an impact on some misfolding 
pathways in a cell-free conversion assay which was 
described by Baskakov [19, 60]. This assay does not 
initiate the folding reaction by co-incubation with PrP
Sc
but uses certain buffer conditions that result in different 
types of PrP formation. Choosing an alternative path-
way with partially folded human PrP allelomorphs, the 
valine consisting ones showed less delay in amyloid 
formation compared to the methionine allelomorphs 
either under spontaneous or seeded folding conditions. 
Rezaei and colleagues [61] performed unfolding 
experiments using different variants of ovine PrP. 
Polymorphisms in the sheep PrP affected thermody-
namic and kinetic parameters of the unfolding as well 
as the refolding process. The results of the experi-
ments indicate a molecular basis for the effects of PrP 
polymorphisms on the transformation of PrP
C to PrP
Sc.
Several other in vitro conversion experiments also 
showed the correlation between the PrP amino acid 
sequence and the convertibility of PrP
C into PrP
res.
Depending on the genotype, ovine PrP was converted 
into its PK-resistant counterpart in a cell-free assay, 
using sheep PrP
Sc as seed for the conversion reaction 
[62]. Ovine PrP genotypes, which are not susceptible to 
classical scrapie in vivo also failed to be converted to 
PrP
res in vitro. Another cell-free assay in which 
bacterially expressed PrP
C was co-incubated with 
PrP
Sc from mouse scrapie brains [63] was used to 
demonstrate that a single amino acid substitution within 
a mouse-ovine chimeric PrP
C results in an inconvertible 
mutant of the previous convertible molecule [64].  
The aforementioned matters in regards to the PrP 
amino acid sequence raise the question of how a 
single, or simply a few, amino acid residues at certain 
sequence positions can have such striking effects on 
the convertibility without changing the globular 
structure of PrP
C. Basically, two types of PrP 
conversion can be distinguished – induced misfolding 
and spontaneous, or non-seeded, PrP
Sc or PrP
res
forming. The latter is seen in inherited human TSEs, 
whereas the induced misfolding needs an infection to 
begin, e.g. through the oral intake of infected tissues. 
The misfolding kinetics of both processes can be 
similar. As indicated by experiments in vitro, an initial 
lag phase is followed by a growth period of rapid fibril 
formation [65]. The addition of prion particles during the 
lag phase shortens the same and is known as seeding. 
A physiological equilibrium of PrP
C and PrP
Sc could be 
destabilized by either exogenous infectious particles 
(acquired TSE) or a high amount of spontaneously 
misfolded endogenous PrP
Sc (spontaneous disease). 
The incubation period or the time until the onset of the 
disease therefore depends on the stability of this 
equilibrium. Certain amino acid constellations tend to 
induce the misfolding more often than other sequences 
and subsequently lead to fibril formation as seen in 
susceptible PrP genotypes. 
It has been demonstrated by NMR spectroscopy 
that some disease related mutations of the human 
PrP
C are located in a part of the protein that is involved 
in the maintenance of the hydrophobic core in the fibril 
[66]. Amino acid mutations therefore do not necessarily 
alter the stability of PrP but might have some local 
effects on the protein interactions which are required 
for oligomerization into fibrillar species. The exposure 
of hydrophobic regions in intermediate states during 
protein folding could increase the tendency towards 
aggregation, and subsequently initiate – at a certain 
stage – the misfolding cascade, which ultimately leads 
to disease. Hydrophobic interactions play a crucial role 
in the formation of -sheets, as they bring fragments of 
a polypeptide chain in close proximity to each other 
[67]. Additionally, Kutznetsov and Rackovsky [68] 
showed that disease-promoting mutations in the human 
PrP
C had a statistically significant tendency towards 
increasing local hydrophobicity with a possible change 
in interactions between PrP molecules and/or between 
PrP and hypothetical cofactors that might initiate 
subsequent fibril formation. 
STABILITY AND CONVERSION PROPENSITY 
OF THE CARBOXY-TERMINAL PRION PRO-
TEIN  
In contrast to the flexible N-terminal part of PrP
C,
structural details of the C-terminal globular domain are 
described for many species [28, 69, 70]. The overall 
folding of this region of PrP
C is very similar in most 
species. The superposition of various three-
dimensional PrP
C structures, based on polypeptide 
backbone atoms of mammalian PrP
Cs, reveals only 
minor differences between the tertiary structures and 
major similarities in the secondary structures. These 
secondary structure elements have been the focus of a 
large number of conversion assays and computer-
based molecular dynamics simulations [71-74]. The 
influence of certain amino acid residues within the -
helices or -strands, as well as the deletion of 
secondary structure elements have been found to 
inhibit the conversion reaction in some experiments 
[74, 75] or have had an effect on the cellular 
localization of PrP [74].  
Helices II and III are anti-parallel orientated and 
connected by a short loop. Their structural stability is 
supported by a disulfide bridge, which is parallel to both 
sheet-forming  -strands. The superpositioning and 
comparison of several mammalian PrP
C structures 
reveal that these -helices and the -sheet form the 
rigid core of the globular assembly. In contrast, helix I 
shows a more mobile positioning due to the long loop 
connections to corresponding secondary structure 
elements. The amino acid sequence composition of 
helix I is exceptional as it is the most hydrophilic -helix 
of all known protein structures [76]. This possibly 
indicates a specific function in protein-protein 
interactions for this helix. In line with this assumption, 
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aggregation of PrP but is not converted into -strands 
[77]. 
A computational comparative analysis of PrP
C and 
Doppel, which is a structurally similar protein and which 
gene is located in the close vicinity of the prion gene, 
focussed on so-called chameleon sequences in both 
proteins [68]. Chameleon sequences are polypeptide 
fragments that can, experimentally, adopt both -
helical and -strand conformations depending on the 
environmental conditions [78]. Other than PrP
C,
Doppel, which is not able to undergo misfolding, 
contains much shorter chameleon fragments. 
Interestingly, the most conserved part of PrP
C in all 
species contains an unusually long chameleon 
fragment, located in an unusually flexible sequence 
context between amino acid residues 114 and 125 [68]. 
Additionally, this 12-mer is a highly conformational 
variable polypeptide compared to other sequences of 
the same length. According to protein databank 
analysis, the mature PrP
C (without N- and C-terminal 
signal peptides) shows the highest conformational 
variability among all sequences that contain chameleon 
segments of 10-14 residues. The authors also found 
that the amino acids seen in the fragment between PrP 
residues 114-125 are involved in the formation of 
intermolecular complexes and possess high binding 
potential in other proteins. The results of this study 
concerning the highly conserved part of PrP, which 
contains the chameleon sequence, are in line with the 
results of Nguyen [79] and Zhang [80]. The researchers 
showed that peptides of this part of the PrP can adopt 
both  -helical or -strand conformation. Interestingly, 
the peptide spanning aa 106-126 has shown to be 
neurotoxic [81].  
Another exciting outcome of the computational 
examination by Kuznetsov and Rackovsky was that 
only helix I lacks a chameleon sequence in contrast to 
helix II and III of PrP
C, which contain a chameleon 
hexamer (helix II) or a pentamer (helix III). The authors 
further show that helix I has a low -strand propensity, 
especially when compared to helix II, which has a 
significant high propensity to -strand conformation. 
Since helix I is not essential for prion infectivity [82], 
and it retains its -helical conformation under a wide 
range of denaturing conditions [76, 83], it can be 
concluded that helix I does not unfold until the late 
states of structural transition, which occur in other parts 
of the PrP under the influence of global conformational 
rearrangements [76]. Due to the high conformational 
flexibility seen between residues 114-125 and with 
regards to the high -strand propensity of helix II, it can 
be assumed that only moderate changes in the 
environmental conditions or interactions can induce 
misfolding of PrP and subsequent fibril formation. 
The crystal structure of human PrP
C is the only 
example of a homodimeric PrP-structure [84]. In the 
homodimer, both -helices I are in close anti-parallel 
orientation, allowing side chain contacts between the 
monomers. Other contacts in this homodimer are 
observed for the C-terminal parts of helices II, which 
form a new, short, anti-parallel -sheet. This allows the 
reorientation of helices III for the dimer formation. The 
newly formed -sheet is a possible initiation of -
transition for the oligomerization of PrP [85]. 
A comparison of monomeric PrP structures with the 
prion-like protein Doppel [86] reveals a major deviation 
for the last two turns of helix II, where Doppel shows a 
strong kink. Consequently, the C-terminal two turns are 
positioned closer to the adjacent helix III. This could 
allow a more compact intramolecular interaction in 
Doppel, and it could explain why amyloidic misfolding 
of this protein is unknown. 
Fig. (3). a) Cartoon plots of helices II and III of superimposed structures of rabbit-PrP (red), mouse-PrP (blue) and mouse-
Doppel (yellow). The C-terminal turn of helix-II and the adjacent loop connection of rabbit-PrP deviate significantly to mouse-PrP 
and follow more the conformation of the kinked helix II of mouse-Doppel. 
b) C-tracing of helices II and III of PrP from rabbit-PrP (red), mouse-PrP (blue) and mouse-Doppel (yellow). Superposition 
based on C-positions with PrP-mouse as a target.  832    Current Molecular Medicine,  2009, Vol. 9, No. 7  Kupfer et al.
Among various species of laboratory animals, the 
rabbit is a rare example of a TSE- resistant subject. 
Recently, the three-dimensional structure of rabbit PrP
C
was determined by NMR spectroscopy (pdb entry code 
2fj3). The aforementioned structural assumption – 
regarding helix II in Doppel – could be an explanation 
for the stability of rabbit PrP
C, which also shows a C-
terminal distortion of helix II (Fig. (3)). 
The NMR structure of elk (Cervus elaphus nelsoni)
PrP displays a species-specific characteristic in the 
region of aa 166-175. This loop links the second -
strand with the second -helix. In contrast to other 
mammalian species, this loop is exceptionally well-
defined in elk [87]. The homologous region is flexibly 
disordered in other mammalian PrP
C species such as 
mice, bovines and humans. By substituting certain 
amino acids in the corresponding region of the mouse 
PrP
C, it has been shown that the rigidity of this loop 
results from the presence of asparagine at residue 170 
in combination with threonine at residue 174. Although 
both amino acid side chains apparently do not interact 
with PrP
C, they have an additional long range effect on 
-helix III, which is better defined in the presence of 
asparagine and threonin than in wild-type mouse PrP
C.
Whether the rigid loop confers TSE susceptibility or 
pathological consequences remains to be examined 
[88]. 
THE ROLE OF THE AMINO-TERMINAL REGION 
DURING PRION PROTEIN MISFOLDING 
The amino terminal region of PrP
C residues 23-120 
(which make up nearly the complete first half of the 
amino sequence of full-length matured PrP
C) is 
unstructured [89] due to a high degree of main chain 
flexibility. Enzymatic degradation studies and 
transgenic mouse studies showed that the amino acids 
stretching from 23-89 are disposable in terms of 
generating infectious prions. Transgenic mice that 
express a truncated version of PrP
C that lacks the 
octarepeat region remain susceptible to prion infection 
[90], although disease progression is slowed down. 
The alteration of metal ion binding has been observed 
in human prion diseases [91]. This stretch harbours a 
region of octarepeat sequences with the ability to bind 
Cu
2+ ions cooperatively [92], and it has been reported 
that incubation with copper ions at concentrations as 
low as 50 M renders full length PrP
C PK resistant [93]. 
This is in line with the observation that preferential Cu
2+
coordination by His96 and His111 induces beta-sheet 
formation in the unstructured amyloidogenic region of 
the prion protein [94]. 
This ability of PrP
C to bind metal ions is also seen in 
a non-vertebrate PrP-like molecule, termed "similar to 
prion protein" or StPrP [95]. Even though the metal ion 
binding site of StPrP consists of less amino acid 
repeats than the one seen in mammalian PrP
C, it is 
able to bind Cu
2+ as effectively as human PrP does. 
Using various PrP fragments and spectroscopic 
techniques, it has been shown that two Cu
2+ ions bind 
to two binding sites centred at His111 and His96. 
Transgenic mice expressing a prion protein with up 
to eight extra octapeptide repeat insertions suffered 
from a spontaneous non-infectious accumulation of PK 
resistant PrP in the brain [96], while transgenic mice 
expressing a bovine PrP with five octapeptide repeats 
displayed a reduced susceptibility to BSE infection [97]. 
The role of metal ion binding in these pathologies is still 
not fully determined. Due to the redox-properties of 
Cu
2+-ions, oxidative stress is thought to induce prion 
misfolding. However, this assumption is still lacking 
solid experimental data.  
Cell-free conversion of a N-terminally truncated, 
ovine-mouse chimeric, bacterially expressed PrP by 
mouse-passaged BSE resulted in two PK resistant 
PrP
res  fragments with a difference of about 1 kDa in 
their molecular mass [98]. In contrast to mouse- 
passaged BSE, mouse scrapie Me7, 22A or 87V 
induced a conversion into only one detectable PK 
resistant PrP
res fragment. These results show that the 
flexible N-terminal region might support a specific 
docking of PrP
C to PrP
Sc. Depending on the structure of 
the PrP
Sc seed, the truncation of amino terminal parts 
of PrP
C can hinder either the binding of PrP
Sc in 
general – which leads to a decrease of conversion 
efficiency – or it inhibits a specific binding of PrP
Sc,
which results in the conversion of PrP
C into differently 
shaped and sized PK resistant PrP
res fragments. How 
Cu
2+ and other metal ions influence the flexibility of the 
N-terminal part and subsequently the interaction 
between PrP
Sc and PrP
C in vivo and in vitro in a strain-
specific fashion remains an interesting topic that has 
not yet been determined. 
Many studies focus on the amino terminal part in 
order to define its relevance for the physiological 
function of PrP and its conversion into PrP
Sc. Various 
aspects of transgenic mice with diverse deletions within 
the N-terminus, as well as truncated forms of 
recombinant PrP
C, have been researched. 
Even though PrP-knockout (PrP
0/0) mice do not 
show remarkable deficits due to the lack of PrP
C
expression, the deletion of residues 105-125 of PrP
C
leads to neonatal lethality in transgenic mice [81]. The 
authors assume a neuroprotective function of PrP
C,
especially for the region between residue 105 and 125, 
which may be associated with the signal transduction in 
order to avoid cellular death; it may be converted to a 
neurotoxic signal by truncation of certain parts of PrP
C.
Neurotoxic effects, along with neurodegenerative 
disease, were also observed in transgenic mice 
expressing other N-terminally truncated forms of PrP
C
[99].  
Doppel, the downstream prion-like protein that 
shows similarities to the C-terminal domain of PrP
C but 
lacks the N-terminal part [100], also causes 
neurodegenerative dysfunction with massive Purkinje 
cell loss if overexpressed in transgenic PrP
0/0 mice 
[100]. Since the reintroduction of a prnp  transgene 
abrogates the disease [101], it is likely that PrP
C
functions as neuroprotective molecule. It would be 
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reintroduction of prnp transgenes in those mice which 
encode different N-terminally truncated forms of PrP
C.
Distinct sequence motifs of the amino terminal part 
could also be examined for their possible neuro-
protective function. 
THE NEUROTOXIC PRION PROTEIN FRAG-
MENT 106-126 
Analysing different sections of the full length PrP, 
Forloni and co-workers [102] identified a peptide 
spanning aa residues 106-126 which displayed a 
neurotoxic effect on rat hippocampal neurons in vitro.
Neurotoxicity could also be demonstrated in vivo [103]. 
This part of the prion protein is therefore commonly 
referred to as neurotoxic peptide. These toxic 
characteristic are restricted exclusively to cells which 
express PrP
C [104]. Because the prion fragment 106-
126 shares many properties of PrP
Sc, e.g. the ability to 
form -structures and partially protease-resistant fibrils, 
it is seen as a model for molecular mechanisms in 
neurodegeneration caused by prion protein misfolding. 
In the structural context, region 106-126 is in very 
close proximity to the first short -strand. It contains the 
sequence 114-125, which – as mentioned before – has 
shown to be a chameleon motiv. Depending on the 
conditions, PrP106-126 can either adapt a metastable 
-helical structure in organic solvents [105], or it self-
assembles into amyloid-like fibrils in water [79]. The 
highly amyloigenic and hydrophobic palindrome 
AGAAAAGA is located between aa residue 113 and 
120 of PrP 106-126. It is described as putative 
aggregation site [106], although this sequence requires 
its flanking parts to form fibrillar aggregates [107]. 
Within the amyloidogenic sequence, Jobling [108] 
replaced the hydrophobic amino acids with hydrophilic 
serines. These mutations decreased the -sheet 
structure and, in correlation with this, abolished 
neurotoxicity. Due to the alterations in the secondary 
structure, the aggregation and fibrillogenic properties of 
PrP 106-126 also changed. In contrast to the 
correlation of amyloidogenicity and neurotoxicity, 
Bergström [109] showed that the oxidation of human 
PrP 106-126 methionines reduced the propensity to 
form amyloid firbrils but at the same time increased 
cytotoxicity. A similar result was shown in another 
experiment with a mutant form of PrP 106-126. The 
replacement of glycine at residues 114 and 119 by 
alanine led to the inability of the peptide to build fibrils 
but it nevertheless increased cytotoxicity [110]. The 
authors assume that by diminishing fibril formation, the 
peptides could be available as soluble oligomers, which 
are more toxic than larger amyloid fibrils [109].  
CONCLUDING REMARKS 
Protein misfolding remains a conundrum, although 
there are plenty of research methods that aim to 
resolve this question. Structural aspects of the prion 
protein, including the amino acid sequence, secondary 
structural elements and post translational modifications 
have been taken into consideration with regard to the 
conformational transition of the protein. The ability of 
prions and other misfolding proteins to adapt more than 
one stable conformation has brought up numerous 
questions concerning the mechanisms of protein 
folding, unfolding and misfolding. There is no doubt that 
not only the intrinsic properties of a polypeptide chain 
determine its three dimensional structure, but also the 
multiple environmental influences such as the cellular 
milieu which contribute to the conformation of a protein. 
The development and establishment of new 
research methods and tools over the last decades have 
opened up possibilities to investigate and understand 
the nature of protein folding and misfolding. 
Discovering the mechanisms behind this complex 
process of conformational transition will establish new 
prospects for combating the increasingly common and 
most devastating protein misfolding diseases. 
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